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ABSTRACT 
Objective: The aim of this study was to evaluate the accuracy of breaking into half and quarter-tablets Enalapril 20 mg sold in the Albanian market, 
in dosages suitable for use in children. 
Methods: 100 whole tablets of Enalapril 20 mg were chosen at random from each of three different manufacturers based on scoring characteristic: 
scored on one side, scored on both sides and not scored. Whole tablets from each of the three product types were weighed and the mean weight 
calculated. The pills were then split in half and quarter by using a pill-splitter. The resulting half-tablets and quarter-tablets were weighed and the 
mean weights were calculated. 
Results: All the whole tablets were found to conform to the set criteria. Only halves from those tablets scored on both sides passed the weight 
uniformity test, with no individual half outside the 85-115 % range. Quarter-tablets failed the weight uniformity test. A higher relative standard 
deviation was observed for half and quarter-tablets of the not-scored tablet.  
Conclusion: The study shows that deviations in weight were observed in half tablets and quarter tablets of Enalapril 20 mg. These deviations were 
related to the presence or not of the score line. Such inadequate breaking of the tablets may result in dose variability and complicate therapeutic 
outcome. 
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INTRODUCTION 
Many drugs administered to children are not available in 
formulations for pediatric use. Most marketed oral medicines are 
intended for adults and are solid dosage forms. Solid dosage forms 
present problems as children have difficulty swallowing whole 
tablets or capsules. Therefore, tablets are sometimes cut into smaller 
parts to obtain appropriate dosage units for children [1-3]. 
Physicians also prescribe half and quarter tablet doses of higher 
strength tablets in order to reduce costs because parity pricing is 
common. A study conducted in the US in 2002 estimated potential 
cost savings of $1.7 billion nationally if tablet splitting was 
performed for 7 antidepressant medical products [4].  
Tablet breaking is a frequent method used to obtain the desired 
dose. Pediatric doses depend on the child's weight and the drugs are 
not always available in the desired dose. Several studies have been 
conducted to assess the accuracy of tablet breaking [5-10]. One 
study analyzed drug weight uniformity of cyclobenzaprine tablets 
split in half using either a pill-splitter or a kitchen knife.  
The results showed that both methods resulted in a wide variation 
in fragment weight between 49.9 % to 149.5 % of the theoretical 
weight using a kitchen knife and 69.4 % to 130.2 % using the pill-
splitter [11]. These studies concluded that tablet breaking resulted 
in an unacceptable weight variation which may produce clinically 
important outcomes or risks of adverse effects, depending on the 
indication and product used. The above studies did not clearly 
define the level at which the reported mass unconformity 
compromised the therapeutic efficacy of the drug. 
There are no established criteria for evaluation of dosage uniformity 
in tablet fractions obtained by patients [12, 13]. Most studies on split 
tablets adopted the United States Pharmacopeia and European 
Pharmacopoeia Standard. That allows a 15 % deviation in weight 
from the label claim and a Standard Deviation (SD) of not greater 
than 6 % [14, 15]. This standard has been applied to other studies 
examining the accuracy of tablet breaking [10, 12, 16].  
Enalapril Maleate is widely used in pediatric cardiology in the 
treatment of essential and renovascular hypertension and in 
congestive heart failure. The daily dose of Enalapril Maleate in 
children is in the range of 0.2-1.0 mg/kg [17, 18]. In the absence of 
liquid formulations for oral administration, it is common practice to 
split available medicines intended for adults. We chose Enalapril 20 
mg tablets that are commonly split and used for long-term therapy. 
The aim of this study was to evaluate the accuracy of breaking into 
half and quarter-tablets Enalapril 20 mg sold in the Albanian market, 
in dosages suitable for use in children. 
MATERIALS AND METHODS 
Three drugs available in the Albanian market were studied: 
Enalapril 20 mg tablets (Kwizda Pharma GmbH); Enalapril 20 mg 
tablets (1A Pharma GmbH); Enalapril 20 mg tablets (Merck Sharp & 
Dohme). They have been chosen based on the presence of a single-
sided score line, a double-sided score line, and no score line. The 
basic characteristics (active substance, strength, form, 
manufacturer, and tablet description) of the three products studied 
are listed in table 1. For simplicity, the different types will be 
referred to as S (score line on one side of the tablet), NS (Not scored) 
and BS (score line on both sides of the tablet). 
 
Table 1: Characteristics of enalapril tablets tested 
Active substance/Strength Manufacturer Tablet description 
Enalapril 20 mg tablets Kwizda Pharma GmbH Scored on one side 
Enalapril 20 mg tablets 1A Pharma GmbH Scored on both sides 
Enalapril 20 mg tablets Merck Sharp & Dohme Not scored 
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A total of 100 whole tablets was randomly selected from each of the 
three drugs. The whole tablets were weighed and the mean weights 
were calculated. Randomly selected tablets were split in half by a 
single investigator, using a pill-splitter (MEDA Pharma GmbH & Co. 
KG) and weighed. The mean weight of the halves was calculated. The 
same person was asked to split the halves again into quarters. One-
quarter per tablet was weighed and the mean weight of the quarter 
of a tablet was calculated. 
The criteria for assessing weight uniformity were adapted from 
European Pharmacopoeia Standard mass uniformity requirements 
and other studies examining the accuracy of tablet breaking [15, 16, 
19]. The criteria are as follows:  
• The ideal split tablets are half-tablets and quarter-tablets within 
the 85 % to 115 % range of weight. 
• The tablets pass the weight uniformity test if not more than one-
half and one-quarter were outside the 85 % to 115 % range and 
within the 75 % to 125 %, and if the RSD was less or equal 10 %.  
• The half-tablets and quarter-tablets fail the weight uniformity test 
if more than one of the 100 half-tablets and quarter-tablets were 
outside the 85 % to 115 % range, or if any half-tablets and quarter-
tablets were outside 75 % to 125 % range. 
RESULTS AND DISCUSSION 
All the tested tablet types (S, BS, and NS) were found to conform to 
the set criteria as all the individual whole tablet weights were 
between 85 % and 115 % of the respective average weights.  
The respective mean weights for S, BS, and NS tablets are presented 
in table 2. 
  
Table 2: Mean weight of the evaluated tablets 
Tablet type Mean weight of whole tablets (mg±SD) Mean weight of halves (mg±SD) Mean weight of quarters (mg±SD) 
S 170.47±7.25 85.14±13.27 41.96±6.36 
BS 162.6±7.5 80.3±7.90 38.71±4.78 
NS 182.7±6.11 87.7±13.91 44.49±10.03 
S: Line score on one side of the tablet, BS: Line score on both sides of the tablet, NS: No line score, SD: Standard deviation, n = 100. 
 
The results of the weight uniformity test performed on half-
tablets and quarter-tablets of the S, BS, and NS products are 
found in table 3 and table 4. The half-tablets of the BS drug 
passed the weight uniformity test, with no individual outside the 
85 % to 115 % range and an RSD less than 10 %. The half-tablets 
of the S and NS products failed a weight uniformity test; the 
halves were outside the 75 %-125 % and had an RSD more than 
10 %. 
  
Table 3: Results of weight uniformity test of half-tablets 
Tablet 
type 
Number of halves within 
85–115 % 
Number of halves within 
75–125 % 
Number of halves outside 




S 74 21 5 15.58 Fail 
BS 100 0 0 9.82 Pass 
NS 63 30 7 15.86 Fail 
S: Line score on one side of the tablet, BS: Line score on both sides of the tablet, NS: No line score, n= 100  
 
The quarter-tablets failed the weight uniformity test. All three 
tablets types had an RSD more than 10 % and quarter-tablets were 
outside the 75 % to 125 % range. The highest RDS (22.54 %) were 
found in NS tablets. 
  
Table 4: Results of weight uniformity test of quarter-tablets 
Tablet 
type 
Number of quarters 
within  
85–115 % 
Number of quarters 
within  
75–125 % 
Number of quarters 
outside  





S 67 24 9 15.16 Fail 
BS 72 22 6 12.34 Fail 
NS 52 30 18 22.54 Fail 
S: Line score on one side of the tablet, BS: Line score on both sides of the tablet, NS: No line score, n= 100 
 
The practice of tablet splitting is frequently pursued in the 
treatment of the pediatric population to obtain appropriately-sized 
dosage units. Recent articles that question tablet splitting safety 
illustrate why splitting accuracy is important [20].  
In this study, the good performance of BS tablets in the splitting test 
of half-tablets may have been due to the presence of the score line 
on both sides of the tablets and the oblong shape of the tablets. This 
combination of the characteristics seems to provide an ideal tablet 
for accurate splitting. On the other hand, NS tablets were reported to 
have the highest number of failing units, of both half and quarter-
tablets tested, outside the 85 % to 115 % and 75 % to 125 % range.  
Other studies found an association between tablet characteristics 
and splitting accuracy. In a study similar to ours, Polli et al. found 
that of the 12 products evaluated, all scored tablets passed the 
uniformity test while most of not scored tablets failed [21]. Zaid et 
al. found that scored tablets of Angiopril 20 (Enalapril) had the 
highest number of failing units, with 9 tablets out of 30 weighing 
outside the 85–115 % range and 6 tablets outside the 75–125 % 
range. This was attributed to the lower level of hardness, and not 
appropriate scoring.  
The shape of the product was reported as round, which may have 
further reduced the ease of splitting [22]. Hill et al. found that 11.1 
% of half-tablets of scored medications failed the weight uniformity 
test compared to 14.4% of half-tablets of not scored medications 
[23]. None of these studies have evaluated the accuracy of splitting 
tablets into quarters.  
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Results from the weight uniformity test (table 3 and table 4) suggest 
greater variability in half and quarter-tablet, drug weight for NS 
medications than for scored medications. Assuming that the 
enalapril content was uniformly distributed throughout each tablet, 
this variability in splitting could result in considerable variation in 
drug content. The estimated range of active substance content in not 
scored tablets is 5.89 mg–13.51 mg for halves and 2.68 mg–7.52 mg 
for quarters. This lack of dosing predictability will be compounded if 
several unevenly split tablets are taken consecutively. 
Administration of dosages lower than those intended can 
compromise the therapeutic effect. In contrast, intake of a dose 
higher than intended may increase dose-related adverse effects. 
Such results can be of clinical significance for drugs which have a 
narrow therapeutic range. If the half-life of the drug is long or the 
therapeutic range is wide, dosage fluctuations are less likely to be 
clinically significant. Enalapril is available in two strengths in the 
Albanian market (10 mg and 20 mg). This requires tablet splitting 
for use in a pediatric population. Enalapril 20 mg was selected as the 
drug of choice because it is frequently used in the treatment of 
essential and renovascular hypertension and in congestive heart 
failure, and dosage in children is achieved by breaking the tablets 
into smaller authorized strengths. The recommended initial dose of 
Enalapril is 2.5 mg for patients with a body weight of 20 kg up to<50 
kg and 5 mg for patients with a body weight ≥ 50 kg.  This study 
suggests that splitting tablets that are not scored results in 
significant irregularities of dosage, which can be clinically 
unacceptable for patients who split these tablets on a regular basis. 
The desired results were achieved only by splitting drugs scored on 
both sides (BS) into half-tablets. 
CONCLUSION 
Wide weight deviations have been observed when the tablets are 
split into subdivisions. Those deviations have been found to be 
related to the presence of the score line. Such inadequate breaking 
of the tablets may result in dose variability and complicate the 
therapeutic outcome. We conclude that the presence of a score line 
in medicinal products fulfills a very important role for the physician 
to prescribe the correct dose. 
In small markets where the introduction of lower doses may not have 
a commercial interest and there is a lack of pediatric formulations, 
appropriately scored tablets can ensure more flexible dosage.  
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